Farfal Sylwia, Klimowicz Adam, Bielecka-Grzela Stanislawa
Department of Dermatology, Division of Dermatopharmacotherapy, Pomeranian Medical University, Szczecin, Poland.
Skin Res Technol. 2006 Nov;12(4):228-34. doi: 10.1111/j.0909-752X.2006.00159.x.
BACKGROUND/PURPOSE: Acyclovir is a synthetic deoxyguanosine analogue used in the treatment of certain viral diseases. This drug is effective primarily against Herpes simplex virus, Varicella zoster virus and to a lesser extent against Epstein-Barr virus and cytomegalovirus. The aim of the study was to determine the acyclovir concentrations in plasma and skin (cutaneous microdialysate) and to compare its penetration into real (skin) and theoretical peripheral compartment after administration of a single 0.4 g oral dose.
To evaluate the skin concentrations of the examined agent in 10 healthy male volunteers linear microdialysis probes with 2 kDa molecular-weight cut-off were inserted intradermally and were perfused with Ringer solution up to 6 h after drug ingestion.
The mean maximum acyclovir concentrations in the plasma, skin and theoretical peripheral compartment were 3.16+/-0.86, 0.94+/-0.34 and 1.85+/-0.69 micromol/L, respectively, and were achieved after 1.6+/-0.4, 2.4+/-0.3 and 3.7+/-0.7 h. The degree of penetration into the real (skin) and theoretical peripheral compartment was 0.36+/-0.15 and 0.74+/-0.12, respectively, and the differences were statistically significant. Similarly, also, the maximum concentration, time to maximum concentration and area under the concentration-time curve differed significantly between the plasma and skin as well as between the skin and the theoretical peripheral compartment.
In selected cases skin concentrations should be determined rather than those in blood plasma when studying the distribution of orally administered drugs. Evaluation of acyclovir concentrations in the skin cannot be replaced by the calculation of the theoretical peripheral compartment.
背景/目的:阿昔洛韦是一种合成的脱氧鸟苷类似物,用于治疗某些病毒性疾病。该药物主要对单纯疱疹病毒、水痘带状疱疹病毒有效,对爱泼斯坦-巴尔病毒和巨细胞病毒的疗效稍差。本研究的目的是测定单次口服0.4 g剂量后血浆和皮肤(皮肤微透析液)中的阿昔洛韦浓度,并比较其在真实(皮肤)和理论外周室的渗透情况。
为评估10名健康男性志愿者体内受试药物的皮肤浓度,将截留分子量为2 kDa的线性微透析探针皮内插入,并在服药后用林格溶液灌注长达6小时。
血浆、皮肤和理论外周室中阿昔洛韦的平均最大浓度分别为3.16±0.86、0.94±0.34和1.85±0.69 μmol/L,分别在1.6±0.4、2.4±0.3和3.7±0.7小时达到。在真实(皮肤)和理论外周室的渗透程度分别为0.36±0.15和0.74±0.12,差异具有统计学意义。同样,血浆与皮肤之间以及皮肤与理论外周室之间的最大浓度、达到最大浓度的时间和浓度-时间曲线下面积也存在显著差异。
在研究口服药物的分布时,在某些情况下应测定皮肤浓度而非血浆浓度。皮肤中阿昔洛韦浓度的评估不能用理论外周室的计算来替代。